First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).

Charalampos S. Floudas,Julius Strauss,Clint T. Allen,Nyall R. London,Renee N. Donahue,Caroline Jochems,Seth M. Steinberg,Lisa M. Cordes,Sheri McMahon,Jenn Marte,Houssein Abdul Sater,Jason M. Redman,Fatima Karzai,Marijo Bilusic,Ravi A. Madan,Douglas E. Brough,Amy Lankford,Jeffrey Schlom,James L. Gulley

First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).

2021

Charalampos S. Floudas
Julius Strauss
Clint T. Allen
Nyall R. London
Renee N. Donahue
Caroline Jochems
Seth M. Steinberg
Lisa M. Cordes
Sheri McMahon
Jenn Marte
Houssein Abdul Sater
Jason M. Redman
Fatima Karzai
Marijo Bilusic
Ravi A. Madan
Douglas E. Brough
Amy Lankford
Jeffrey Schlom
James L. Gulley

TPS6092Background: R/M HPVC (cervical, anal, oropharyngeal, etc.) are incurable by current therapies. For newly diagnosed LA HPV-OPSCC standard-of-care (SOC) is radiotherapy ± chemotherapy (C/RT) o...

Keywords:

first in human
in patient
human papillomavirus
induction therapy
squamous cell cancer
Chemotherapy
Medicine
Internal medicine
Oncology
Radiation therapy
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations